GASTROCYNESINE Cpr B/60

Abies nigra 4CH .................................................................................................................................................................... 0,625 mg

Carbo vegetabilis 4CH ......................................................................................................................................................... 0,625 mg

Nux vomica 4CH ................................................................................................................................................................... 0,625 mg

Robinia pseudo-acacia 4CH ................................................................................................................................................ 0,625 mg

For one tablet of 250 mg.

Excipients: Sucrose, lactose.

Homeopathic medicine traditionally used in the treatment of difficult digestion (heartburn and stomach acidity, bloating, aerophagia).

Dosage

Medicine reserved for adults and children over 6 years.

2 tablets to be sucked two to three times a day, preferably before meals.

Space out the intakes as soon as improvement occurs and stop taking when the symptoms disappear.

The duration of treatment must not exceed ten days without medical advice.

Paediatric population

In children between 6 and 12 years, this medicine must not be administered without medical advice.

Method of administration

Oral use.

• Hypersensitivity to the active substances or to any of the excipients listed in section Composition.
• Children under 6 years of age.

This medicine contains sucrose. Its use is not recommended in patients with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase/isomaltase deficiency (rare hereditary diseases).

This medicinal product contains lactose. Its use is not recommended in patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary disorders).

GASTROCYNESINE, tablet may be taken during pregnancy and breastfeeding.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website:www.ansm.sante.fr.

Pharmacotherapeutic class: homeopathic medicine.

In the absence of scientific data, the indication for this medicine is based on the homeopathic use of its components.

5 years.

No special precautions for storage.

No special requirements.